Dr. Mims on FDA Approval of Ivosidenib in Patients With AML

Name: Dr. Mims on FDA Approval of Ivosidenib in Patients With AML
Uploaded: 2018-07-20T20:04:00.000Z
Description: Alice Mims, MD, medical oncologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of the IDH1m inhibitor ivosidenib for the treatment of patients with acute myeloid leukemia (AML).

July 20, 2018

Alice Mims, MD

Video

In Partnership With:

Alice Mims, MD, medical oncologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of the IDH1m inhibitor ivosidenib for the treatment of patients with acute myeloid leukemia (AML).